TORONTO, July 25,
2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the
"Company") (TSX: HLS), announces that it will release its Q2 fiscal
2024 financial results on Thursday, August
8, 2024. The Company will hold a conference call that same
day at 8:30 a.m. ET to discuss its
results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer and Mr.
John Hanna, Interim Chief Financial
Officer. Slides to accompany management's prepared remarks will
be available to view via the webcast.
CONFERENCE ID: 58793
DATE: Thursday, August 8, 2024
TIME: 8:30 a.m. ET
WEBCAST
LINK: https://app.webinar.net/Bo1rqAKyNm9
TRADITIONAL DIAL-IN NUMBER: 1-800-836-8184 or
1-289-819-1350
RAPIDCONNECT: To instantly join the conference call
by phone, please use the following URL to easily register and be
connected into the conference call automatically:
https://emportal.ink/3xE2Dl5
TAPED REPLAY: 1-888-660-6345 or 1-289-819-1450
REPLAY CODE: 58793#
The taped replay will be available for 14 days and the archived
webcast will be available for 365 days.
A link to the live audio webcast of the conference call will
also be available on the events page of the investors section of
HLS Therapeutics' website at www.hlstherapeutics.com. Please
connect at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be required to
hear the webcast.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the
acquisition and commercialization of late-stage development,
commercial stage promoted and established branded pharmaceutical
products in the North American markets. HLS's focus is on products
that address unmet needs in the treatment of psychiatric disorders
and cardiovascular disease. HLS's management team is composed of
seasoned pharmaceutical executives with a strong track record of
success in these therapeutic areas and at managing products in each
of these lifecycle stages. For more information visit:
www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.